New York, USA - 21 Apr `17Celgene: Apremilast with NB-UVB

Official title: A Split Body Study of the Effects of Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo. Phase II

In brief:

  • Procedure: Each participant will be compared with one side of the body to the other side. Enrolled subjects will be randomized to treatment with narrowband UVB two to three times weekly to one half of their body for a total of 16 weeks, while the contralateral side of the body is covered by a special garment to prevent any UVB treatment.
  • Drug: Apremilast (oral tablet) 30 mg orally, twice daily. 

Recruitment status: completed

Start date: April 21, 2017    
Last Update: August 27, 2019

Contact: To learn more about this study, you or your doctor may contact the study research staff. Please refer to this study by its ClinicalTrials.gov identifier NCT03123016

FAQOther Questions

  • Is it Bitiligo? Vitaligo? Veteligo?

    There are so many different ways that people try and spell or even pronounce Vitiligo.  Here are some common mis-spellings: bitiligo, vitigo, vitaligo, vitilago, vitiglio, vita...

  • Who is prone to vitiligo?

    Scientists know that some people are genetically predisposed to a specific group of autoimmune diseases – including generalized vitiligo – but do not know who and why.It doesn’t...

  • Is there a special diet for vitiligo?

    In short, no.  Some people find that certain foods may worsen their vitiligo symptoms or that others may improve their skin condition. We found no scientific evidence that a sp...